...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm... ...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm... ...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm... ...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm... ...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
...filing. The company named Chairman John Siebert as executive chairman and interim principal executive officer. Aradigm... ...the Company’s cash resources until additional sources of capital can be identified." On Jan. 29, Aradigm... ...from Aradigm under a 2013 deal. On Monday, the first trading day after the resignations, Aradigm...
...free ciprofloxacin for inhalation. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm... ...Monday, Grifols gained $0.14 to $21.12 on NASDAQ and €0.32 to €23.86 in Madrid.
Alicia Parker
ARD-3150
Linhaliq
Liposomal ciprofloxacin
Aradigm Corp.
Grifols...
...In December, Aradigm reported mixed data from the identical, 48-week, double-blind, international Phase III ORBIT-3 and... ...endpoint of reducing pulmonary exacerbation frequency vs. placebo in ORBIT-4 (HR=0.63, p=0.0007). In both trials, Aradigm... ...rights to Pulmaquin under a 2013 deal with Aradigm (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm... ...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm... ...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm... ...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm... ...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
...filing. The company named Chairman John Siebert as executive chairman and interim principal executive officer. Aradigm... ...the Company’s cash resources until additional sources of capital can be identified." On Jan. 29, Aradigm... ...from Aradigm under a 2013 deal. On Monday, the first trading day after the resignations, Aradigm...
...free ciprofloxacin for inhalation. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm... ...Monday, Grifols gained $0.14 to $21.12 on NASDAQ and €0.32 to €23.86 in Madrid.
Alicia Parker
ARD-3150
Linhaliq
Liposomal ciprofloxacin
Aradigm Corp.
Grifols...
...In December, Aradigm reported mixed data from the identical, 48-week, double-blind, international Phase III ORBIT-3 and... ...endpoint of reducing pulmonary exacerbation frequency vs. placebo in ORBIT-4 (HR=0.63, p=0.0007). In both trials, Aradigm... ...rights to Pulmaquin under a 2013 deal with Aradigm (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
